Clinical director at the Malagan Institute Dr Robert Weinkove Photo: Supplied
A breakthrough cancer treatment developed in here New Zealand which uses a patient's own immune system to find and destroys the disease is a step closer to market.
Wellington Zhaotai Therapies, which is a joint venture between the Malaghan Institute and China's Hunan Zhaotai Medical, has signed a multi-milllon dollar deal with Indian pharmaceutical giant Dr Reddy's Laboratories.
The agreement will see trials of a new generation of CAR T-cell therapy, where a patient's own immune or T-cells are genetically modified to recognise and destroy their cancer.
Kathryn talks to Dr Rob Weinkove the clinical director at Malagan about the clinical trials and his ambition to see this become a mainstream treatment.
